Survey of the Pancreatic Cancer Drug Market With Celgene's Abraxane in Focus

Published December 4, 2012

Survey Of The Pancreatic Cancer Drug Market With Celgene's Abraxane In Focus

Filed under: drug treatment news articles

Earlier this year, in August, the FDA approved Xtandi (enzalutamide)- to be marketed by Medivation (MDVN) for the treatment of metastatic castration-resistant prostate cancer. Per a FDA news release from September 27, 2012, Stivarga, a multi-kinase …
Read more on Seeking Alpha

3 Pharmaceuticals With Promising Growth Catalysts To Consider Now

Filed under: drug treatment news articles

In this article, I will focus on three pharmaceutical companies that are seeing new growth catalysts which could push their share prices higher in the coming weeks and months. PROLOR Biotech (PBTH) engages in the … Lastly, I will focus on Regeneron …
Read more on Seeking Alpha

Questcor Pharmaceuticals Dip Offers Opportunity In Front Of Acthar Script Data

Filed under: drug treatment news articles

I have no business relationship with any company whose stock is mentioned in this article. (More…) Questcor Pharmaceuticals (QCOR) shares fell roughly 8% on Friday following an update from Aetna (AET) regarding the insurer's coverage of QCOR's lead …
Read more on Seeking Alpha